Edoxaban
Edoxaban, sold under the brand name Lixiana among others, is an anticoagulant medication and a direct factor Xa inhibitor. It is taken by mouth.
Clinical data | |
---|---|
Trade names | Savaysa, Lixiana, Roteas, others |
Other names | DU-176b |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614055 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 62%; Tmax 1–2 hours |
Protein binding | 55% |
Metabolism | minimal CES1, CYP3A4/5, hydrolysis, glucuronidation |
Elimination half-life | 10–14 hours |
Excretion | 62% feces, 35% urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H30ClN7O4S |
Molar mass | 548.06 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Compared with warfarin it has fewer drug interactions.
It was developed by Daiichi Sankyo and approved in July 2011, in Japan for prevention of venous thromboembolisms following lower-limb orthopedic surgery. It was also approved in the United States by the Food and Drug Administration (FDA) in January 2015, for the prevention of stroke and non–central-nervous-system systemic embolism. It was approved for use in the European Union in June 2015. It is on the World Health Organization's List of Essential Medicines.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.